Preliminary fourth quarter and full-year 2024 U.S. net product revenue for OGSIVEO were $61.5 million and $172.0 million, respectively. Q4, FY24 revenue consensus $55.22M, $186.44M, respectively. As of December 31, 2024, total preliminary cash, cash equivalents, and marketable securities was $461.9 million. SpringWorks expects its cash position to fund operations through profitability, which the Company anticipates achieving in the first half of 2026.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics rumor highlighted in Betaville alert
- Biotech Alert: Searches spiking for these stocks today
- SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim
- SpringWorks Therapeutics price target lowered to $55 from $58 at BofA
- SpringWorks Therapeutics initiated with an Outperform at Evercore ISI